FDA zatw.Pluvicto™ (177Lu-PSMA-617)&Locametz® (Novartis)

FDA zatw.Pluvicto™ (177Lu-PSMA-617)&Locametz® (Novartis)

Nieprzeczytany postautor: zosia bluszcz » 27 mar 2022, 15:37

W oparciu o wynik III fazy badania klinicznego VISION FDA zatwierdziła 2 preparaty opracowane przez firmę Novartis :

- Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan, dawniej 177Lu-PSMA-617)
- Locametz® (zestaw do przygotowania Ga68 gozetotide (PSMA) injection)

Preparat Pluvicto przeznaczony jest do stosowania u pacjentów z PSMA dodatnim mCRPC (80% przypadków CaP) na etapie progresji po leczeniu androgenami II generacji oraz taksanami (Docetaxel/Cabazitaxel).

W USA Pluvicto będzie dostępne za kilka tygodni.
Firma Novartis wystąpiła o rejestrację Pluvicto przez EMA.

Przewidywany koszt Pluvicto w obrocie hurtowym - USD 42 500 za dawkę (podaje się 3 -6 dawek).
Locametz ma kosztować USD 5 600.



Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
Mar 23, 2022

=> FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2

=> Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options

=> FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of overall survival and radiographic progression free survival were met1

=> Novartis is committed to reimagining medicine in prostate cancer with targeted radioligand therapy - a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).

=> Two pivotal Phase III studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, with a goal to move into earlier stages of disease



Basel, March 23, 2022 — Novartis announced today that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic)1.
These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy)1.

“The approval of Pluvicto is an important clinical advancement for people with progressing mCRPC, as it can significantly improve survival rates for those who have limited treatment options,” said Oliver Sartor, MD, Medical Director at Tulane Cancer Center. “Pluvicto is a step forward in the evolution of precision medicine for prostate cancer.”
Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with mCRPC that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle)1. Pluvicto is expected to be available to physicians and patients within weeks.

The FDA has also approved Locametz® (kit for the preparation of gallium Ga 68 gozetotide injection)2. After radiolabeling, this imaging agent may be used to identify PSMA-positive lesions in adult patients with mCRPC through a positron emission tomography (PET) scan2. Gallium-68 labeled Locametz can identify tumor lesions expressing the PSMA biomarker and locate where in the body tumors may have spread (eg, in soft tissue, lymph nodes, or bone), identifying patients eligible for targeted treatment with Pluvicto1,2.
PSMA is highly expressed in more than 80 percent of patients with prostate cancer, making it an important phenotypic biomarker for assessing the progression of metastatic prostate cancer4-10. Locametz is expected to be available to physicians and patients within weeks.

“With our unique strategy to tackle cancer by leveraging four therapeutic platforms, I am thrilled that with Pluvicto, we are bringing the targeted RLT platform to bear for treating eligible patients with mCRPC,” said Susanne Schaffert, PhD, President, Novartis Oncology. [i]“Today’s approval builds upon our history in prostate cancer, a devastating disease where we believe our innovation can make a meaningful difference to patients.”

FDA approval of Pluvicto is based on the results of the Phase III VISION trial which demonstrated that PSMA-positive mCRPC patients previously treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy who received Pluvicto plus standard of care (SOC) had improved overall survival compared to SOC alone1.
Participants treated with Pluvicto plus SOC had a 38% reduction in risk of death and a statistically significant reduction in the risk of radiographic disease progression or death (rPFS) compared to SOC alone1.
Interpretation of the magnitude of the rPFS effect was limited due to a high degree of censoring from early drop out in the control arm1.

In addition, about a third (30%) of patients with evaluable disease at baseline demonstrated an overall response (per RECIST 1.1) with Pluvicto plus SOC, compared to 2% in the SOC alone arm1.

The most common adverse events (all grades) in the Pluvicto arm of the study were fatigue (43%), dry mouth (39%), nausea (35%), anemia (low red blood cell counts) (32%), decreased appetite (21%), and constipation (20%)1.

“Prostate cancer is the second leading cause of cancer-related death in Americans with a prostate gland13. Although the treatment landscape for mCRPC continues to evolve, there is a high unmet need for additional precision medicine treatment options to improve outcomes for these patients,” said Jamie Bearse, CEO and President at ZERO – The End of Prostate Cancer. “The approval of Pluvicto offers new hope to the mCRPC community.”
Pluvicto and Locametz are registered products of Advanced Accelerator Applications, the radioligand business of Novartis, approved in the United States for physicians to prescribe to appropriate patients. Additional safety details for Pluvicto and Locametz, and full Prescribing Information can be found on the Novartis website.

About Pluvicto
PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with other anticancer treatments (androgen receptor pathway inhibition (ARPI) and taxane-based chemotherapy)1. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle)1. After administration into the bloodstream, Pluvicto binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein1. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells disrupting their ability to replicate and/or triggering cell death1.
Novartis has submitted marketing authorization for Pluvicto to the European Medicines Agency and other health authorities.

About Locametz
Locametz® (gallium Ga 68 gozetotide), diagnostic kit for radiopharmaceutical injectable preparation is indicated for positron emission tomography (PET) of PSMA-positive lesions in adult patients with prostate cancer with suspected metastasis who are candidates for initial definitive therapy; with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; and for selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated2.
Novartis has submitted marketing authorization for Locametz to the European Medicines Agency and other health authorities.


https://www.novartis.com/news/media-rel ... ate-cancer



Pluvicto -Novartis ulotka leku.pdf



Locametz kit- Novartis ulotka.pdf
Nie masz wymaganych uprawnień, aby zobaczyć pliki załączone do tego posta.
zosia bluszcz
Złoty Gladiator
Złoty Gladiator
 
Posty: 10136
Rejestracja: 13 cze 2009, 02:06
Blog: Wyświetl blog (0)

Wróć do O CZYM POWINNIŚMY WIEDZIEĆ PRZED, W TRAKCIE I PO LECZENIU

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 27 gości

logo zenbox